SCHEMBL1865443

SCHEMBL1865443

CCOc1ccsc1C(=O)NNC(=O)c1sccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.60
ALDH1A1 P00352 5/20 0.51
MEN1 O00255 5/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 8/20 0.50
MAPT P10636 2/20 0.50
PKM P14618 2/20 0.50
AGTR1 P30556 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CYP1A2 P05177 3/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C19 P33261 2/20 0.48
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 2/20 0.46
CYP2C9 P11712 1/20 0.46
PTPRC P08575 1/20 0.45
PTPN1 P18031 1/20 0.45
INPPL1 O15357 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1864666 0.83 KMT2A (0.60) KMT2AALDH1A1MEN1SMN1; SMN2L3MBTL1
SCHEMBL1859781 0.81 GAA (0.69) KMT2AALDH1A1MEN1L3MBTL1GAA
SCHEMBL14140503 0.81 KMT2A (0.51) KMT2AALDH1A1MEN1SMN1; SMN2L3MBTL1
SCHEMBL1866492 0.81 KMT2A (0.57) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL6655913 0.80 KMT2A (0.69) KMT2AALDH1A1MEN1SMN1; SMN2L3MBTL1
SCHEMBL22408118 0.80 KMT2A (0.69) KMT2AALDH1A1MEN1SMN1; SMN2L3MBTL1
SCHEMBL22408180 0.79 KMT2A (0.67) KMT2AALDH1A1MEN1SMN1; SMN2L3MBTL1
SCHEMBL25983198 0.78 KMT2A (0.70) KMT2AALDH1A1MEN1SMN1; SMN2L3MBTL1
SCHEMBL22408141 0.78 KMT2A (0.65) KMT2AALDH1A1MEN1SMN1; SMN2L3MBTL1
SCHEMBL1868142 0.78 ALDH1A1 (0.55) KMT2AALDH1A1MEN1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105597-A1 Modulation of pathogenicity QUONOVA, LLC 2011-05-05 US disclosed
US-20110105597-A1 Modulation of pathogenicity QUONOVA, LLC 2011-05-05 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
EP-1478364-B1 SELECTIVE ANTIBACTERIAL AGENTS QUONOVA LLC (US) 2009-09-16 EP disclosed
EP-1478364-B1 SELECTIVE ANTIBACTERIAL AGENTS QUONOVA LLC (US) 2009-09-16 EP disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20080182878-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-31 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
EP-1478364-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2004-11-24 EP disclosed
US-20040063765-A1 Modulation of pathogenicity 4 SC AG (DE) 2004-04-01 US disclosed
WO-2003039549-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076012-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 KMT2A 3562/4885ALDH1A1 3110/4885MEN1 2784/4885
US-20110105597-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 KMT2A 3588/4885ALDH1A1 3159/4885MEN1 2784/4885
US-20100280036-A1 Modulation of Pathogenicity NR4A1, NR4A2, NR4A3 KMT2A 3588/4885ALDH1A1 3159/4885MEN1 2784/4885
US-20080182878-A1 Modulation of pathogenicity NR4A1, NR4A2, MSR1 KMT2A 3589/4885ALDH1A1 3160/4885MEN1 2774/4885
US-20080176938-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 KMT2A 3597/4885ALDH1A1 2904/4885MEN1 2609/4885
US-20040063765-A1 Modulation of pathogenicity NR1H4, NR4A1, MSR1 KMT2A 3617/4885ALDH1A1 2935/4885MEN1 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.